Versantis is developing breakthrough liver disease treatments addressing high unmet medical needs in the field of liver and metabolic diseases.
Its lead candidate, VS-01, is currently being evaluated at the clinical stage and has the potential to be the first treatment for acute liver disease, simultaneously supporting multiple failing organs. VS-01 targets three rare indications and received orphan drug status. In addition, Versantis’ pipeline promises to improve patients’ outcome in other medical fields like chronic liver diseases and for the treatment urea cycle disease in infants.